thebench.bio #1 Ecosystem for the Bio-Tech Industry
All Antibody Engineering questions

Question 16 of 20 Intermediate Troubleshooting

How would you distinguish poor antibody affinity from poor target accessibility on intact cells?

Short answer

Measure affinity against purified antigen in a cell-free format, then compare binding on intact and permeabilized cells, across cell lines with known target levels. Weak binding everywhere points to affinity, while weak binding only on intact cells points to access, masking or epitope conformation.

Why

A weak signal on cells has several possible causes, and they call for different fixes. Intrinsic affinity is measured cleanly only in a controlled format such as surface plasmon resonance or biolayer interferometry against purified antigen, with a reference surface and sensible densities. If the measured KD is weak there, the molecule itself is the problem.

If affinity is good but cell binding is poor, the question becomes access. The epitope may be buried in the membrane or in a glycan shield, occupied by a ligand or binding partner, internalized quickly, or only present in a conformation the cell does not display. Target levels also matter.

The relationship between a cell-free KD and a cell EC50 is not direct, as a modeling study of antibody bivalency notes, because the two reflect the contexts of their assays, including antigen density and valency. Comparing intact with permeabilized cells, and cells that differ in target expression, separates these. Detection artifacts add another layer, including Fc receptor binding by the test antibody and secondary reagent cross-reactivity, so isotype and secondary-only controls are needed.

How to work it through

  1. Measure affinity against purified antigen in a cell-free kinetic format with proper reference channels.
  2. Confirm target expression on the cells by an independent method such as RNA levels or a validated second antibody.
  3. Compare binding on intact and permeabilized cells at matched antibody concentrations.
  4. Titrate across cell lines with high, low and no target expression.
  5. Include isotype and secondary-only controls, and block Fc receptors where they are present.
  6. Test whether a known ligand or binding partner competes for the site.

An example

An antibody shows a KD of 2 nM against purified extracellular domain, but a cell EC50 above 500 nM on a target-positive line. Permeabilized cells stain brightly at 10 nM, and a line engineered to overexpress the target stains at 20 nM intact. Pre-incubating cells with the natural ligand removes most of the remaining signal, so the team concludes the epitope is partly occluded by the ligand rather than the affinity being poor.

Where the answer stops holding

Permeabilization can expose epitopes that are never accessible in vivo and can also destroy conformational ones. Engineered high-expression lines overstate binding achievable on real tissue. A cell EC50 and a cell-free KD measure different things and should not be compared as if interchangeable.

A strong answer covers

  • Separate cell-free affinity from cell binding deliberately
  • Compare intact with permeabilized cells and across expression levels
  • Consider ligand occupancy, glycan shielding and internalization
  • Include isotype, secondary-only and Fc receptor blocking controls
  • A cell EC50 is not a KD

Common mistakes

  • Quoting a cell EC50 as an affinity value
  • Concluding no expression from a negative stain without an orthogonal check
  • Overlooking Fc receptor binding as a source of signal or interference